CardioNerds (Amit Goyal and Daniel Ambinder), join cardiology fellows from Indiana University cardiology fellows (Dr. Asad Torabi, Dr. Michelle Morris, and Dr. Sujoy Phookan) to discuss a case of a patient who developed a nagging cough post PCI and is ultimately diagnosed with Dressler Syndrome. This case describes the work up and management of post infarct pericarditis and briefly reviews the dilemma of utilizing triple anti-thrombotic therapy with high dose aspirin in the post myocardial infarction period. Indiana University faculty and expert, Dr. Julie Clary provides the E-CPR for this episode.
With this episode, the CardioNerds family warmly welcomes Indiana University to the CardioNerds Healy Honor Roll. CardioNerds Healy Honor Roll programs are a collection of cardiology fellowship programs across the United States that support and foster the CardioNerds spirit and mission of democratizing cardiovascular education. Honor roll programs nominate fellows who are highly motivated and are passionate about medical education. Indiana University’s fellowship program director, Dr. Deepak Bhakta has nominated Dr. Asad Torabi for this position.
Claim free CME just for enjoying this episode! Disclosures: None
A 56-year-old man with recent anterior STEMI and new heart failure with reduced ejection fraction presented with fevers, persistent cough, and pleuritic chest pain following percutaneous coronary intervention for the past two weeks. He was ultimately found to have post cardiac injury syndrome – post infarct pericarditis (formerly known as Dressler syndrome) with elevated inflammatory markers, a small pericardial effusion, and incidentally noted to have an apical left ventricular thrombus. This case describes the work up and management of post infarct pericarditis and briefly reviews the dilemma of utilizing triple anti-thrombotic therapy with high dose aspirin in the post myocardial infarction period.
1. Post cardiac injury syndrome (PCIS) following myocardial infarction can be very debilitating and recurrence is the concern when treatment is not pursued.
2. Acute pericarditis is a clinical diagnosis which does not require imaging and can have a wide spectrum on presentation ranging from fever/cough to the classic positional chest pain.
3. PCIS following myocardial infarction is less common in the post PCI era but we are starting to see more cases in late presenters.
4. We have good level of evidence to suggest the use of colchicine to reduce the recurrence of PCIS. COPPS and COPPS-2, are two such randomized placebo control trials, which show benefit in the cardiac surgical patient.
5. While triple therapy on high dose aspirin is not discussed in the 2013 ACCF/AHA STEMI guidelines, carefully assess your patient’s bleeding risk and invoke patient shared decision making whenever possible.
1. What is Post-Cardiac Injury Syndrome (PCIS) and what are the clinical manifestations?
- PCIS is an umbrella term for specific clinical scenarios which may result in symptomatic acute pericarditis.
- PCIS encompasses:
- Post-myocardial infarction pericarditis which may be early or late (Dressler syndrome – the focus of this case)
- Post-pericardiotomy syndrome (PPS)
- Post-traumatic pericarditis including traumatic and iatrogenic (following most percutaneous procedures such as ablations, PCI, lead placement, etc).
2. How is PCIS (or post infarct pericarditis) diagnosed?
- This is a clinical diagnosis, made when ≥ 2 of the following are present:
- Fever without alternative cause
- Pericarditic or pleuritic chest pain
- Friction rub
- Pericardial effusion
- Pleural effusion with elevated CRP
- Note this is different from the diagnostic criteria for other causes of acute pericarditis which requires 2 of the 4 following features:
- Pericarditic chest pain
- Friction rub
- New widespread ST-elevations or PR depressions on ECG
- Pericardial effusion (new or worsening)
- Supporting findings for pericarditis include:
- Elevation of inflammatory markers (CRP, ESR, WBC)
- Pericardial inflammation on cross sectional cardiac imaging (CT, CMR)
3. What are the complications of not treating Dressler syndrome?
- Imazio et al published an excellent case series in 2009 which answers this question. Overall the prevalence of complications for early and late post-infarct pericarditis was low. No cases of constrictive pericarditis were observed but the incidence of recurrent pericarditis was observed at 3.2%.
- The 2015 ESC pericardial guidelines recommend considering careful follow-up after PCIS to exclude possible evolution towards constrictive pericarditis with echocardiography every 6-12 months according to clinical features and symptoms (Class IIa).
4. What is the evidence for high dose Aspirin in Dressler syndrome?
- This is a class 1b evidence in the 2013 ACCF/AHA STEMI guidelines. This evidence comes from data from a small case series of 24 patients which compared aspirin to indomethacin head-to-head. Overall aspirin was non-inferior with similar bleeding risk. The guidelines recommend the use of high dose aspirin because of NSAIDS may interfere with DAPT and there is also concern regarding scar thinning and infarct expansion.
- The 2015 ESC pericardial guidelines recommend aspirin as a first choice for anti-inflammatory therapy of post-myocardial infarction pericarditis and those who are already on antiplatelet therapies (Class I).
5. What is the role of colchicine for MI, for chronic coronary disease, for pericarditis, and for PCIS?
- Following MI (without pericarditis): the COLCOT trial showed that colchicine is effective at preventing major adverse cardiac events after MI. In this randomized, double-blind, placebo-controlled trial, a total of 4,745 patients (within 30 days of MI and following intended coronary revascularization) were randomized to colchicine 0.5mg daily or to placebo. After a median follow-up of 22.6 months, there was a significant reduction in the primary efficacy outcome (cardiovascular death, MI, CVA, resuscitated cardiac arrest, or urgent hospitalization for UA leading to revascularization) (HR 0.77, 95% CI 0.61-0.96, p = 0.02).
- Chronic coronary disease (without pericarditis): the LoDoCo2 trial showed that colchicine is effective in reducing major adverse cardiac events in patients with chronic coronary disease. In this randomized, double-blind, placebo-controlled trial, a total of 5,522 patients were randomized to colchicine 0.5mg daily or to placebo. After a median follow-up of 28.6 months, there was a significant reduction in CV mortality, MI, ischemic stroke, or coronary revascularization driven by ischemia events in the treatment arm (HR 0.69, 95% CI 0.57-0.83, p < 0.001).
- Acute pericarditis: the unblinded COPE trial and blinded randomized placebo-controlled ICAP trial demonstrated benefit of colchicine in the first episode of pericarditis, added to NSAID therapy. The CORP trial (blinded RCT) demonstrated benefit of colchicine in recurrent pericarditis.
- Post-pericardiotomy syndrome: the COPPS and COPPS-2 trials showed efficacy of colchicine when initiated 3 days following or 2-3 days preceding surgery respectively, at the cost of increased gastrointestinal side effects. The 2015 ESC pericardial guidelines recommend:
- Class IIA: Colchicine added to aspirin or NSAIDs should be considered for the therapy of PCIS, as in acute pericarditis.
- Class IIA: Colchicine should be considered after cardiac surgery using weight-adjusted doses (i.e. 0.5 mg once for patients ≤70 kg and 0.5 mg twice daily for patients .70 kg) and without a loading dose for the prevention of PPS if there are no contraindications and it is tolerated. Preventive administration of colchicine is recommended for 1 month.
6. What is the recommended approach to triple anti-thrombotic therapy in patient with MI s/p PCI and an indication for anticoagulation?
- The duration for triple therapy should be limited to the shortest duration possible/needed (the duration of aspirin in this regimen remains controversial. In the 2020 ACC expert consensus pathway, a short duration of no more than 30 days is recommended. Clopidogrel is the P2Y12 inhibitor of choice in this regimen to minimize the risk of bleeding and aspirin should be limited to <100 mg.
- However, the guidelines do not specifically address approach to Dressler syndrome in a post-MI patient treated with PCI who has an indication for anticoagulation (as with apical thrombus in this case) where high dose aspirin would be recommended for pericarditis, DAPT for stent, and warfarin for the thrombus. As with all cases, shared decision making with careful weighing of risks and benefits is advised, in concert with an experienced heart team.
Berman J, Haffajee CI, Alpert JS. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am Heart J. 1981 Jun;101(6):750-3. doi: 10.1016/0002-8703(81)90610-4. PMID: 7234652. https://pubmed.ncbi.nlm.nih.gov/7234652/
Imazio M, Negro A, Belli R, Beqaraj F, Forno D, Giammaria M, Trinchero R, Adler Y, Spodick D. Frequency and prognostic significance of pericarditis following acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol. 2009 Jun 1;103(11):1525-9. doi: 10.1016/j.amjcard.2009.01.366. Epub 2009 Apr 8. PMID: 19463510. https://pubmed.ncbi.nlm.nih.gov/19463510/
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. PMID: 31733140. https://pubmed.ncbi.nlm.nih.gov/31733140/
Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, Ferrua S, Maestroni S, Zingarelli E, Barosi A, Simon C, Sansone F, Patrini D, Vitali E, Ferrazzi P, Spodick DH, Adler Y; COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010 Nov;31(22):2749-54. doi: 10.1093/eurheartj/ehq319. Epub 2010 Aug 30. PMID: 20805112. https://pubmed.ncbi.nlm.nih.gov/20805112/
Imazio M, Belli R, Brucato A, Ferrazzi P, Patrini D, Martinelli L, Polizzi V, Cemin R, Leggieri A, Caforio AL, Finkelstein Y, Hoit B, Maisch B, Mayosi BM, Oh JK, Ristic AD, Seferovic P, Spodick DH, Adler Y. Rationale and design of the COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): a randomized, placebo-controlled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions, and postoperative atrial fibrillation. Am Heart J. 2013 Jul;166(1):13-9. doi: 10.1016/j.ahj.2013.03.025. Epub 2013 May 6. PMID: 23816016.
Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Feb 9;77(5):629-658. doi: 10.1016/j.jacc.2020.09.011. Epub 2020 Nov 26. PMID: 33250267. https://pubmed.ncbi.nlm.nih.gov/33250267/
Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B, Hung J, Garcia MJ, Kronzon I, Oh JK, Rodriguez ER, Schaff HV, Schoenhagen P, Tan CD, White RD. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013 Sep;26(9):965-1012.e15. doi: 10.1016/j.echo.2013.06.023. PMID: 23998693. https://pubmed.ncbi.nlm.nih.gov/23998693/